These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 20888102)
1. Once-daily extended-release niacin lowers serum phosphorus concentrations in patients with metabolic syndrome dyslipidemia. Hu S; Shearer GC; Steffes MW; Harris WS; Bostom AG Am J Kidney Dis; 2011 Jan; 57(1):181-2. PubMed ID: 20888102 [No Abstract] [Full Text] [Related]
2. Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes. Bostom AG; Maclean AA; Maccubbin D; Tipping D; Giezek H; Hanlon WA J Clin Lipidol; 2011; 5(4):281-7. PubMed ID: 21784373 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. Bays HE; Shah A; Lin J; McCrary Sisk C; Paolini JF; Maccubbin D J Clin Lipidol; 2010; 4(6):515-21. PubMed ID: 21122699 [TBL] [Abstract][Full Text] [Related]
4. Safety of extended-release niacin/laropiprant in patients with dyslipidemia. McKenney J; Bays H; Koren M; Ballantyne CM; Paolini JF; Mitchel Y; Betteridge A; Kuznetsova O; Sapre A; Sisk CM; Maccubbin D J Clin Lipidol; 2010; 4(2):105-112.e1. PubMed ID: 21122637 [TBL] [Abstract][Full Text] [Related]
5. Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. Maccubbin D; Tipping D; Kuznetsova O; Hanlon WA; Bostom AG Clin J Am Soc Nephrol; 2010 Apr; 5(4):582-9. PubMed ID: 20299362 [TBL] [Abstract][Full Text] [Related]
6. Safety, tolerance, and efficacy of extended-release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomized multicenter controlled trial. Nash MS; Lewis JE; Dyson-Hudson TA; Szlachcic Y; Yee F; Mendez AJ; Spungen AM; Bauman WA Arch Phys Med Rehabil; 2011 Mar; 92(3):399-410. PubMed ID: 21276961 [TBL] [Abstract][Full Text] [Related]
7. Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients. Ix JH; Ganjoo P; Tipping D; Tershakovec AM; Bostom AG Am J Kidney Dis; 2011 Jun; 57(6):963-5. PubMed ID: 21496982 [No Abstract] [Full Text] [Related]
8. Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad. Salgado BJ; Salgado JV; Dos Santos AM; Casulari LA Minerva Cardioangiol; 2010 Oct; 58(5):531-42. PubMed ID: 20948500 [TBL] [Abstract][Full Text] [Related]
9. Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome. Kaushik SV; Plaisance EP; Kim T; Huang EY; Mahurin AJ; Grandjean PW; Mathews ST Diabetes Metab Res Rev; 2009 Jul; 25(5):427-34. PubMed ID: 19405044 [TBL] [Abstract][Full Text] [Related]
10. Effect of niacin on FGF23 concentration in chronic kidney disease. Rao M; Steffes M; Bostom A; Ix JH Am J Nephrol; 2014; 39(6):484-90. PubMed ID: 24854458 [TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of extended-release niacin with laropiprant. Yadav R; Kwok S; Ammori BJ; Issa B; Soran H Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050 [TBL] [Abstract][Full Text] [Related]
12. Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Bays HE Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):485-501. PubMed ID: 15225109 [TBL] [Abstract][Full Text] [Related]
13. Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model. Paraskevas KI; Pantopoulou A; Vlachos IS; Agrogiannis G; Iliopoulos DG; Karatzas G; Tzivras D; Mikhailidis DP; Perrea DN Angiology; 2011 Feb; 62(2):144-54. PubMed ID: 21220373 [TBL] [Abstract][Full Text] [Related]
14. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. Rubenfire M; Am J Cardiol; 2004 Aug; 94(3):306-11. PubMed ID: 15276093 [TBL] [Abstract][Full Text] [Related]
15. Extended release nicotinic acid - a novel oral agent for phosphate control. Sampathkumar K; Selvam M; Sooraj YS; Gowthaman S; Ajeshkumar RN Int Urol Nephrol; 2006; 38(1):171-4. PubMed ID: 16502077 [TBL] [Abstract][Full Text] [Related]
16. Increased total and high-molecular weight adiponectin after extended-release niacin. Plaisance EP; Grandjean PW; Brunson BL; Judd RL Metabolism; 2008 Mar; 57(3):404-9. PubMed ID: 18249215 [TBL] [Abstract][Full Text] [Related]
18. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324 [TBL] [Abstract][Full Text] [Related]
19. The appropriateness of nicotinic acid derivative use in patients with the metabolic syndrome: insights from the ARBITER 2 study. Al-Shaer MH; Jerome WP Am J Cardiol; 2006 Jul; 98(2):275-6. PubMed ID: 16828609 [No Abstract] [Full Text] [Related]
20. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers. Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]